Evidence map›Paper›PMID 40352638›Full record

ReviewGlobal challenges (Hoboken, NJ)2025

Emerging Technologies for Timely Point-of-Care Diagnostics of Skin Cancer.

Jarrod L Thomas, Adrian H M Heagerty, Pola Goldberg Oppenheimer

Abstract readReview
In one paragraph

Review in Global challenges (Hoboken, NJ), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jarrod L ThomasAdvanced Nanomaterials Structures and Applications Laboratories School of Chemical Engineering College of Engineering and Physical Sciences University of Birmingham Edgbaston Birmingham B15 2TT UK.
Adrian H M HeagertyDepartment of Dermatology University Hospitals Birmingham NHS Foundation Trust Mindelsohn Way Birmingham B15 2GW UK.
Pola Goldberg OppenheimerAdvanced Nanomaterials Structures and Applications Laboratories School of Chemical Engineering College of Engineering and Physical Sciences University of Birmingham Edgbaston Birmingham B15 2TT UK.ORCID https://orcid.org/0000-0002-1014-4724

Funding

Wellcome Trust
6 · The paper itself

Abstract

Skin cancer is a global health crisis and a leading cause of morbidity and mortality worldwide. A leading factor of malignancy remains the UV radiation, driving various biomolecular changes. With shifting population behaviors, deficiency in screening programs and reliance on self-presentation, climate change and the ageing world populace, global incidents have been surging alarmingly. There is an urgent need for new technologies to achieve timely intervention through rapid and accurate diagnostics of skin cancer. Raman spectroscopy has been emerging as a highly promising analytical technology for diagnostic applications, poised to outpace the current costly, invasive and slow procedures, frequently hindered by varying sensitivity, specificity and lack of portability. Herein, complex and intricate progress are overviewed and consolidated across medical and engineering disciplines with a focus on the latest advances in the traditional and emerging skin cancer diagnostics. Methods detecting structural and chemical responses are categorized along with emerging chemo-biophysical sensing techniques. Particular attention is drawn to Raman spectroscopy, as a non-invasive, rapid and accurate sensing of molecular fingerprints in dermatological matrix with an additional focus on artificial intelligence, as a decision support tool collectively, laying the platform toward development and rapid translation of point-of-care diagnostic technologies for skin cancer to real-world applications.

Indexed as

dermatologyglobal healthcare technologiespoint‐of‐care diagnosticsRaman spectroscopyskin cancertranslational medicine

Identifiers

PMID40352638
PMCPMC12065104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.